Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
25
10
2019
revised:
30
01
2020
accepted:
05
02
2020
pubmed:
14
2
2020
medline:
4
6
2020
entrez:
14
2
2020
Statut:
ppublish
Résumé
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m
Identifiants
pubmed: 32052473
doi: 10.1002/ajh.25757
pmc: PMC7383599
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
urelumab
230902QLLC
Rituximab
4F4X42SYQ6
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
510-520Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Bristol-Myers Squibb
Pays : International
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Clin Cancer Res. 2017 Apr 15;23(8):1929-1936
pubmed: 27756788
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Am J Hematol. 2018 Feb;93(2):296-305
pubmed: 29314206
J Clin Oncol. 2019 Feb 20;37(6):481-489
pubmed: 30620669
J Biomed Biotechnol. 2012;2012:926321
pubmed: 22500111
Nat Commun. 2018 Nov 15;9(1):4809
pubmed: 30442944
J Natl Compr Canc Netw. 2022 Mar;20(3):285-308
pubmed: 35276674
Clin Cancer Res. 2018 Mar 1;24(5):1138-1151
pubmed: 29301830
BMB Rep. 2014 Mar;47(3):122-9
pubmed: 24499671
Blood. 2009 Oct 15;114(16):3431-8
pubmed: 19641184
J Comp Eff Res. 2014 Jan;3(1):95-107
pubmed: 24345259
Blood. 1998 Sep 15;92(6):1927-32
pubmed: 9731049
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23
pubmed: 24217204
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Cancer Res. 2011 Feb 1;71(3):801-11
pubmed: 21266358
Nat Commun. 2019 May 20;10(1):2141
pubmed: 31105267
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013788
Lancet. 2017 Jul 15;390(10091):298-310
pubmed: 28153383
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Oncoimmunology. 2018 Jan 23;7(4):e1296996
pubmed: 29632708
Future Sci OA. 2018 Jul 19;4(7):FSO322
pubmed: 30112190
Am J Hematol. 2020 May;95(5):510-520
pubmed: 32052473
Sci Transl Med. 2019 Jun 12;11(496):
pubmed: 31189721
Clin Cancer Res. 2009 Oct 15;15(20):6446-53
pubmed: 19808874
Clin Cancer Res. 2015 Jul 15;21(14):3113-20
pubmed: 25908780